Retatrutide

Retatrutide is an investigational triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. This first-in-class triple agonist represents a significant advancement in incretin-based therapies, showing the highest weight loss observed in clinical trials to date.

Retatrutide uniquely activates three receptors: GLP-1R for appetite suppression and glucose control, GIPR for enhanced lipid metabolism, and glucagon receptor for increased energy expenditure and hepatic lipid oxidation. The glucagon component drives thermogenesis and fat oxidation.

Weekly dosing with sustained receptor engagement. Peak concentration achieved within 24-72 hours post-injection.

Note: These are research protocols from literature. This is not medical advice.

Peptides that may be combined based on complementary mechanisms in research settings.

• 1Phase 2 trials showed up to 24.2% body weight reduction at 48 weeks with 12mg dose
• 2Superior weight loss compared to tirzepatide and semaglutide in head-to-head analyses
• 3Significant improvements in liver fat content (up to 86% reduction)
• 4Favorable effects on lipid profiles and blood pressure

Refrigerate at 2-8C

Scientific References

• 1
  Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

  Rosenstock J, et al.

  Lancet, 2023